Nuanyang Jiankang Raises ￥10M in Pre-A Round

According to VCBeat, Nuanyang Jiankang, a medical device company in the field of interventional neurology, has raised tens of millions of yuan in the Pre-A round of financing of, with participation from China Growth Capital and Rays Capital. Ruiling Capital acts as the exclusive financial consultant.

Founded in January 2019, Nuanyang Jiankang is a leading provider of interventional neurology devices in China. Through minimally invasive interventional implantation, the company develops and sells neurointerventional/implanted devices and accessories for ischemic and hemorrhagic stroke.

Neuro-interventional surgery has become one of the major treatments for stroke. The interventional neurology devices market in the next ten years is the same as the interventional cardiology devices market ten years ago, which has a trend of rapid development. In 2017, the market demand for the neuro-interventional stent system in China was about 20,000 sets, with an annual growth rate of 5%-6%. However, it still faces the clinical shortage of devices for the treatment of stroke and the competition of import monopolies. The market is in urgent need of high-quality domestic devices.

Nuanyang Jiankang focuses on clinical problems and technical conditions in the treatment of stroke and has independently developed the device for blood flow and the stent system covering the treatment of ischemic and hemorrhagic stroke. Nuanyang Jiankang provides a full solution for the treatment of stroke, based on its comprehensive platform of development, production, and clinical application.

The core team members of Nuanyang Jiankang have more than 10 years of experience in the design and development of medical devices and participated in the early research on neural intervention in China. The R&D center of the company is located in the Shanghai Yangtze River Delta Hi-tech City, bringing together all kinds of creative talents. Its production base is located in Nantong Hi-tech Park, with 1000 square meters of workshop, 10,000 class level purification workshop, and high productivity.

CGC is a China-focused seed and early venture investor since 2006. The firm funds seed to Series B in enterprise software and services, frontier technologies, marketplace, and consumer sectors. The typical investment size ranges from $1M to 5M with a hard cap ceiling at $15M per company. CGC manages 8 Billion RMB (approximately $1.2 billion) across its different RMB and USD funds.

Founded in Beijing in September 2014, Rays Capital focuses on incubating and supporting innovative projects in the healthcare sector. The medical fund initiated and managed by Rays Capital is positioned as early-stage venture capital, investing in potential companies engaged in medical devices, biotechnology, new drug R&D, and other fields.